Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
Rhea-AI Summary
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-related diseases, has scheduled its fourth quarter and full year 2024 financial results announcement. The results will be released before market open on Wednesday, February 12, 2025.
The company will host a conference call at 8:30 a.m. ET on the same day, accessible via domestic (1-800-717-1738) and international (1-646-307-1865) dial-in numbers. A live webcast will be available through the Investor Relations section of the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – MLYS
On the day this news was published, MLYS declined 2.05%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025.
| Wednesday, February 12th @ 8:30 a.m. ET | |
| Domestic: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) release Q4 and full year 2024 earnings?
How can investors access the MLYS Q4 2024 earnings call?
What therapeutic areas does Mineralys Therapeutics (MLYS) focus on?
